An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess if Aranesp® administered once every 4 weeks to chronic kidney disease subjects is safe and efficacious in maintaining haemoglobin levels greater than or equal to 100 g/L.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Chronic Kidney Disease (CKD) anemia, clinical trial darbepoetin alfa Aranesp® Amgen

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aranesp® (darbepoetin alfa)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of chronic kidney disease and not expected to initiate dialysis for the duration of the study
* Creatinine clearance greater than 15 and less than 40 mL/min as estimated by the Cockroft-Gault equation:

* Creatinine Clearance = (140-age in years) x body weight in kg/serum creatinine (mg/dL) x 72.
* For women, the value will be multiplied by 0.85
* Receiving stable every other week subcutaneous doses of Aranesp®.
* A stable dose is defined as less than or equal to 25% change in Aranesp® dose over the 6-week period immediately prior to enrollment and with no more than

1 missed dose over this period
* At least two haemoglobin values within the target range of 100 to 130 g/L obtained at least 1 week apart and within 5 weeks of the baseline visit
* Subjects must have a haemoglobin of 100 to 130 g/L at eligibility/baseline
* Serum ferritin greater than or equal to 100 mg/L or transferrin saturation greater than or equal to 19.5%
* Serum vitamin B12 and folate levels must be above the lower limit of the normal range of the local laboratory
* Before any study specific procedure is performed, the subject must provide informed consent for participation in the study

Exclusion Criteria

* Anticipating, scheduled for, or a prior recipient of a kidney transplant
* Uncontrolled hypertension (blood pressure greater than 160/100 mmHg during the eligibility/baseline period on 2 separate measurements)
* Congestive heart failure (New York Heart Association \[NYHA\] class III or IV)
* Clinical evidence of severe hyperparathyroidism (parathyroid hormone level greater than 1500 pg/mL or biopsy-proven bone marrow fibrosis)
* Major surgery within 12 weeks before enrollment (excluding vascular access surgery)
* Active chronic inflammatory process
* Currently receiving antibiotic therapy for systemic infection
* ALT or AST greater than 2 times the upper limit of normal range
* Known positive HIV antibody or positive hepatitis B surface antigen
* Clinical evidence of current malignancy and/or receiving systemic chemotherapy/radiotherapy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia
* Red blood cell transfusions within 8 weeks before eligibility visit or active bleeding
* Systemic hematologic disease (e.g., sickle cell anaemia, myelodysplastic syndromes, hematologic malignancy, myeloma, haemolytic anaemia)
* Psychiatric or any other disorder which may impact (in the judgment of the Investigator) the ability to give informed consent for participation in this study
* Pregnant or breast feeding women
* All subjects must practice adequate contraception in the judgment of the Investigator, during the course of their participation in the trial
* Previous entry in this study
* Treatment with an investigational agent other than Aranesp® or device within 30 days before the first dose of study drug or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Amgen Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

MD

Role: STUDY_DIRECTOR

Amgen

References

Explore related publications, articles, or registry entries linked to this study.

Disney A, Jersey PD, Kirkland G, Mantha M, Charlesworth JA, Gallagher M, Harris D, Gock H, Mangos GJ, Macmillan J, Liu W, Viswalingam A. Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: a multicentre, open-label, Australian study. Nephrology (Carlton). 2007 Feb;12(1):95-101. doi: 10.1111/j.1440-1797.2006.00757.x.

Reference Type RESULT

PMID: 17295668 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20030112

Identifier Type: -

Identifier Source: org_study_id